ANKE BIO(SZ:300009)2022-12-04 06:48Group 1: Company Overview and Investor Relations - Anke Bioengineering (Group) Co., Ltd. is engaged in investor relations activities, including targeted research and discussions with institutional investors [2][4]. - The meeting took place on November 14, 2017, at the company's conference hall, attended by key executives including the chairman and vice presidents [4][6]. Group 2: CAR-T Cell Immunotherapy - The company focuses on CD-19 CAR-T cell immunotherapy, which has shown a complete response (CR) rate exceeding 80% in difficult-to-treat relapsed patients [5]. - The market potential for CD-19 CAR-T therapy is significant, with an estimated 112,000 deaths annually from blood cancers in China, including approximately 57,000 from B-cell lymphoblastic leukemia and non-Hodgkin lymphoma [5]. Group 3: Growth Hormone Sales and Market Expansion - The rapid growth in sales of recombinant human growth hormone is attributed to expanded market coverage and targeted promotional activities [6]. - The two-child policy in China is expected to increase the patient base and market potential for growth hormone treatments [6]. Group 4: R&D and Product Development - The company is actively developing a range of innovative drugs, with a focus on growth hormone products and CAR-T therapies [7]. - Current projects include long-acting growth hormone injections and monoclonal antibodies, with several products in various stages of clinical trials [7][8]. Group 5: Clinical Trial Requirements - The approval process for CAR-T therapies in China is expected to require two phases of clinical trials, although existing clinical data may provide supportive evidence [8]. - The company is prioritizing the stability of production processes and quality assurance systems in preparation for regulatory submissions [8].